Central Laboratory, Jiangyin People's Hospital Affiliated to Nantong University, Shoushanlu No. 163, Jiangyin, Wuxi, China.
Medical School of Nantong University, Qixiu Road No. 19, Nantong, China.
J Neurooncol. 2017 Sep;134(2):253-258. doi: 10.1007/s11060-017-2518-5. Epub 2017 Jun 2.
Pituitary adenomas (PAs), single-clone adenomas arising from pituitary gland cells, comprise one of the most frequent tumors found in the sella region. The prevalence of PAs is approximately 15%, third only after gliomas and meningioma among intracranial tumors. Autopsy and radiological analysis found that the incidence of PAs is approximately 22.5%. Most PAs are benign, although a few are malignant. Just 0.1% of patients with PAs develop pituitary carcinoma. However, owing to mass effects and unregulated secretion of pituitary hormones, PAs also lead to serious morbidity. The low rate of diagnosis at onset and the lack of effective treatments for patients with recurrent disease increase the morbidity rates. Therefore, there is an urgent need to ascertain the pathological mechanism of PAs for improved diagnosis and development of specific therapies. At present, the pathogenesis of PAs is poorly understood; however, disruption of the cell cycle is known to play an important role. MicroRNAs are short noncoding RNAs that regulate gene expression at the post-transcriptional level and play a role in regulating genes involved in carcinogenesis or tumor suppression. Previous studies have demonstrated a strong connection between dysregulation of microRNAs and dysregulation of the cell cycle in PAs. In this review, we summarize the recent progress in the study of microRNA dysregulation resulting in disruption of the cell cycle in PAs.
垂体腺瘤(PAs)是起源于垂体细胞的单克隆腺瘤,是鞍区最常见的肿瘤之一。PAs 的患病率约为 15%,在颅内肿瘤中仅次于胶质瘤和脑膜瘤。尸检和影像学分析发现,PAs 的发病率约为 22.5%。大多数 PAs 是良性的,但少数是恶性的。只有 0.1%的 PAs 患者发展为垂体癌。然而,由于肿瘤的占位效应和垂体激素的不受控制分泌,PAs 也导致了严重的发病率。发病时诊断率低,以及复发性疾病患者缺乏有效治疗方法,增加了发病率。因此,迫切需要确定 PAs 的病理机制,以改善诊断和开发特异性治疗方法。目前,PAs 的发病机制尚不清楚;然而,细胞周期的破坏被认为起着重要的作用。microRNAs 是一种短的非编码 RNA,可在转录后水平调节基因表达,并在调节参与致癌或肿瘤抑制的基因方面发挥作用。先前的研究表明,microRNAs 的失调与 PAs 中细胞周期的失调之间存在很强的联系。在这篇综述中,我们总结了 microRNA 失调导致 PAs 细胞周期紊乱的最新研究进展。